Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II long-term safety and efficacy study of HSK39297 in primary IgA nephropathy
ChiCTR2500107477Phase 2Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ciprocopan in IgA nephropathy (IgAN), sponsored by Peking University First Hospital. Primary endpoint: Long-term safety of HSK39297 in primary IgA nephropathy. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
ciprocopan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR2500107477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107477.